Robert Rifkin, MD of the Rocky Mountain Cancer Center in Denver CO describes the real-world study he presented at the European Hematology Association (EHA) Annual Meeting that used fitbit and quality of life measures to assess whether multiple myeloma patients respond well to treatment with ixazomib.

Dr. Rifkin and colleagues presented data from an ongoing study that allows patients to self monitor their response to treatment when transitioning from a parenteral bortezomib based therapy to an oral ixazomib based therapy. Using a variety of physiological and quality of life measures, the study is showing that the transition is well tolerated by most of the patients involved. The strength of the data presented could have significant implications for future treatment options for persons with multiple myeloma but possible impact how researchers use outcome measures during the COVID-19 pandemic.

Click here to read the abstract/poster from the EHA Congress.

Multiple myeloma is a rare blood cancer characterized by malignant plasma cells in the bone marrow and excessive production of monoclonal immunoglobulins in blood and urine. Patients with multiple myeloma develop significant osteolytic bone lesions and have immunodeficiency that can greatly compromise their longevity and quality of life.

Due to advances in research, there are numerous therapies approved, or in development, to treat persons with multiple myeloma.